RT @jambor_ivan: 18F-FACBC (Fluciclovine) PET/CT, PET/MRI, mpMRI in PCa (FLUCIPRO trial) - free access to imaging data sets&more at https:/…
18F-FACBC (Fluciclovine) PET/CT, PET/MRI, mpMRI in PCa (FLUCIPRO trial) - free access to imaging data sets&more at https://t.co/ZGQukDDuAH https://t.co/rdSnm6EM3h
RT @TurkuPETCentre: Fluciclovine PET is promising in prostate cancer detection, but does not outperform multiparametric MRI. https://t.co/A…
Fluciclovine PET is promising in prostate cancer detection, but does not outperform multiparametric MRI. https://t.co/A8qNcH2RJB
RT @radiolobt: Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate can…
Prospective evaluation of (18)F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). https://t.co/cnvsRXKqOw
Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO Trial). https://t.co/qtHEXAxV6I